CAS: 75726-96-4; 2-Bromo-N-Isopropylacetamide

相似化合物

57120-58-8 5327-00-4 2895-21-8

2-Benzenesulfonyl-2-Bromo-1-Isopropyl-Aziridine 反应 2.5H,反应生成 2-溴-N-异丙基乙酰胺
参考文献:Gaillot,J.-M. Et Al.,Canadian Journal Of Chemistry,1979,Vol. 57,P. 1958-1966
标题:Gaillot,J.-M. Et Al.,Canadian Journal Of Chemistry,1979,Vol. 57,P. 1958-1966

专利信息

专利号:CN-106916145-A
优先权日:2017-03-06
标 题:Synthesis of SLx‑2119

专利号:US-8754237-B2
优先权日:2006-02-14
标题:Bifunctional histone deacetylase inhibitors
发明人：BRADNER JAMES ELLIOT; MAZITSCHEK RALPH; TANG WEIPING; SCHREIBER STUART L
权利人:BRADNER JAMES ELLIOT; MAZITSCHEK RALPH; TANG WEIPING; SCHREIBER STUART L; HARVARD COLLEGE; DANA FARBER CANCER INST INC
摘要:In recognition of the need to develop novel therapeutic agents and efficient methods for the synthesis thereof, the present invention provides novel bifunctional, trifunctional, or multifunctional compounds for inhibiting histone deacetylases, and pharmaceutically acceptable salts and derivatives thereof. The present invention further provides methods for treating disorders regulated by histone deacetylase activity (e.g., proliferative diseases, cancer, inflammatory diseases, protozoal infections, hair loss, etc.) comprising administering a therapeutically effective amount of an inventive compound to a subject in need thereof. The present invention also provides methods for preparing compounds of the invention.

专利号:US-8304451-B2
优先权日:2006-05-03
标题 :Histone deacetylase and tubulin deacetylase inhibitors
发明人：MAZITSCHEK RALPH; KWIATKOWSKI NICHOLAS PAUL; BRADNER JAMES ELLIOT
权利人:MAZITSCHEK RALPH; KWIATKOWSKI NICHOLAS PAUL; BRADNER JAMES ELLIOT; HARVARD COLLEGE; DANA FARBER CANCER INST INC
摘要:In recognition of the need to develop novel therapeutic agents and efficient methods for the synthesis thereof, the present invention provides novel inhibitors of histone deacetylases, tubulin deacetylases, and/or aggresome inhibitors, and pharmaceutically acceptable salts and derivatives thereof. The inventive compounds fall into two classes—“isotubacin†class and “isoisotubacin†class—all of which include a 1,3-dioxane core. The present invention further provides methods for treating disorders regulated by histone deacetylase activity, tubulin deacetylase activity, and/or the aggresome (e.g., proliferative diseases, cancer, inflammatory diseases, protozoal infections, protein degradation disorders, protein deposition disorders, etc.) comprising administering a therapeutically effective amount of an inventive compound to a subject in need thereof. The present invention also provides methods for preparing compounds of the invention.